| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 28 | 2023 | 322 | 3.770 |
Why?
|
| Orthopedics | 9 | 2020 | 124 | 2.370 |
Why?
|
| Femoral Neoplasms | 5 | 2020 | 24 | 1.640 |
Why?
|
| Internship and Residency | 8 | 2020 | 1004 | 1.580 |
Why?
|
| Orthopedic Procedures | 5 | 2020 | 128 | 1.540 |
Why?
|
| Sarcoma | 14 | 2020 | 215 | 1.490 |
Why?
|
| Clinical Competence | 8 | 2020 | 751 | 1.300 |
Why?
|
| Osteosarcoma | 8 | 2020 | 158 | 1.020 |
Why?
|
| Femur | 5 | 2020 | 116 | 0.980 |
Why?
|
| Soft Tissue Neoplasms | 10 | 2019 | 127 | 0.940 |
Why?
|
| Limb Salvage | 4 | 2020 | 33 | 0.910 |
Why?
|
| Bone Lengthening | 2 | 2020 | 4 | 0.800 |
Why?
|
| Bone Nails | 2 | 2017 | 17 | 0.790 |
Why?
|
| Artificial Limbs | 1 | 2020 | 20 | 0.750 |
Why?
|
| Personnel Staffing and Scheduling | 3 | 2012 | 93 | 0.720 |
Why?
|
| Work Schedule Tolerance | 2 | 2012 | 36 | 0.720 |
Why?
|
| Specialization | 1 | 2020 | 65 | 0.700 |
Why?
|
| Bone Transplantation | 6 | 2022 | 64 | 0.700 |
Why?
|
| Osteotomy | 3 | 2018 | 31 | 0.680 |
Why?
|
| Career Choice | 1 | 2020 | 139 | 0.650 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 14 | 0.620 |
Why?
|
| Clinical Clerkship | 1 | 2019 | 116 | 0.610 |
Why?
|
| Curriculum | 3 | 2019 | 539 | 0.580 |
Why?
|
| Patient Safety | 3 | 2020 | 212 | 0.550 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2015 | 10 | 0.550 |
Why?
|
| Endocarditis, Bacterial | 1 | 2015 | 33 | 0.540 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 58 | 0.520 |
Why?
|
| Education, Medical, Graduate | 4 | 2020 | 369 | 0.520 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 71 | 0.520 |
Why?
|
| Bacteremia | 1 | 2015 | 99 | 0.510 |
Why?
|
| Decision Making | 1 | 2020 | 642 | 0.480 |
Why?
|
| Curettage | 2 | 2024 | 12 | 0.480 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2017 | 3362 | 0.470 |
Why?
|
| Workload | 2 | 2012 | 128 | 0.470 |
Why?
|
| Neoplasm Staging | 14 | 2013 | 1939 | 0.460 |
Why?
|
| Bone Cysts, Aneurysmal | 2 | 2011 | 7 | 0.460 |
Why?
|
| Bone Cysts | 2 | 2024 | 10 | 0.450 |
Why?
|
| Humans | 71 | 2024 | 86644 | 0.450 |
Why?
|
| Teaching | 1 | 2013 | 147 | 0.420 |
Why?
|
| Argon Plasma Coagulation | 1 | 2011 | 6 | 0.420 |
Why?
|
| Medical Errors | 1 | 2012 | 115 | 0.400 |
Why?
|
| Osteochondroma | 2 | 2010 | 7 | 0.380 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 48 | 0.380 |
Why?
|
| Tibia | 2 | 2010 | 82 | 0.380 |
Why?
|
| Male | 40 | 2023 | 40966 | 0.370 |
Why?
|
| Catheter Ablation | 3 | 2011 | 233 | 0.370 |
Why?
|
| Extremities | 6 | 2014 | 167 | 0.360 |
Why?
|
| Child | 17 | 2024 | 6927 | 0.360 |
Why?
|
| Hip Joint | 1 | 2010 | 55 | 0.350 |
Why?
|
| Female | 40 | 2021 | 44533 | 0.340 |
Why?
|
| Joint Instability | 1 | 2010 | 81 | 0.340 |
Why?
|
| Competency-Based Education | 2 | 2019 | 35 | 0.320 |
Why?
|
| Adult | 33 | 2021 | 25648 | 0.320 |
Why?
|
| Orthopedic Surgeons | 2 | 2019 | 17 | 0.310 |
Why?
|
| Biopsy | 7 | 2011 | 1163 | 0.310 |
Why?
|
| Radiography | 8 | 2024 | 813 | 0.300 |
Why?
|
| Retrospective Studies | 18 | 2024 | 8489 | 0.300 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 636 | 0.300 |
Why?
|
| Adolescent | 15 | 2021 | 8981 | 0.280 |
Why?
|
| Osteoma, Osteoid | 2 | 2005 | 9 | 0.270 |
Why?
|
| Endometriosis | 1 | 2005 | 58 | 0.270 |
Why?
|
| Muscular Diseases | 1 | 2005 | 63 | 0.260 |
Why?
|
| Treatment Outcome | 12 | 2024 | 7993 | 0.260 |
Why?
|
| United States | 10 | 2020 | 6672 | 0.250 |
Why?
|
| Tarsal Bones | 2 | 2021 | 9 | 0.240 |
Why?
|
| Diagnosis, Differential | 7 | 2023 | 1565 | 0.240 |
Why?
|
| Fracture Fixation, Internal | 1 | 2004 | 66 | 0.230 |
Why?
|
| Pelvic Bones | 2 | 2000 | 44 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2011 | 2601 | 0.230 |
Why?
|
| Shoulder Joint | 2 | 2004 | 90 | 0.220 |
Why?
|
| Bone Substitutes | 1 | 2021 | 9 | 0.210 |
Why?
|
| Fractures, Spontaneous | 1 | 2021 | 11 | 0.210 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2021 | 9 | 0.210 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3640 | 0.200 |
Why?
|
| Middle Aged | 26 | 2020 | 25028 | 0.200 |
Why?
|
| Rhabdomyosarcoma | 2 | 1998 | 40 | 0.190 |
Why?
|
| Leg Length Inequality | 1 | 2020 | 2 | 0.190 |
Why?
|
| Fractures, Bone | 2 | 2017 | 131 | 0.190 |
Why?
|
| Time Factors | 7 | 2020 | 5210 | 0.190 |
Why?
|
| Child, Preschool | 6 | 2021 | 3612 | 0.190 |
Why?
|
| Occupational Health | 1 | 2020 | 32 | 0.180 |
Why?
|
| Veins | 1 | 2020 | 94 | 0.180 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 51 | 0.180 |
Why?
|
| Humerus | 1 | 1999 | 31 | 0.180 |
Why?
|
| Arteries | 1 | 2020 | 176 | 0.170 |
Why?
|
| Thymoma | 1 | 2019 | 30 | 0.170 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2019 | 6 | 0.170 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 148 | 0.170 |
Why?
|
| Cognitive Aging | 1 | 2019 | 8 | 0.170 |
Why?
|
| Learning Curve | 1 | 2019 | 18 | 0.170 |
Why?
|
| Choristoma | 1 | 2019 | 68 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 166 | 0.170 |
Why?
|
| Cartilage, Articular | 1 | 1999 | 67 | 0.170 |
Why?
|
| Models, Educational | 1 | 2019 | 50 | 0.170 |
Why?
|
| Fibrous Dysplasia, Monostotic | 1 | 2018 | 1 | 0.170 |
Why?
|
| Disabled Persons | 1 | 1999 | 67 | 0.160 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 140 | 0.160 |
Why?
|
| Analysis of Variance | 2 | 2019 | 912 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 1313 | 0.160 |
Why?
|
| Giant Cell Tumor of Tendon Sheath | 1 | 2017 | 2 | 0.160 |
Why?
|
| Metatarsal Bones | 1 | 2017 | 6 | 0.160 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 16 | 0.150 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2017 | 7 | 0.150 |
Why?
|
| Leg Bones | 2 | 2011 | 7 | 0.150 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2017 | 15 | 0.150 |
Why?
|
| Neoplasm Metastasis | 6 | 2006 | 1056 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2019 | 751 | 0.150 |
Why?
|
| Cadaver | 1 | 2017 | 185 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 132 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2020 | 319 | 0.140 |
Why?
|
| Internet | 1 | 2019 | 312 | 0.140 |
Why?
|
| Cysts | 2 | 2010 | 104 | 0.140 |
Why?
|
| Sex Factors | 1 | 2020 | 1054 | 0.140 |
Why?
|
| Muscle Neoplasms | 1 | 1996 | 18 | 0.140 |
Why?
|
| Postoperative Complications | 4 | 2020 | 2207 | 0.140 |
Why?
|
| Thromboembolism | 1 | 2017 | 119 | 0.140 |
Why?
|
| Joint Diseases | 2 | 2010 | 49 | 0.140 |
Why?
|
| Prosthesis Design | 1 | 2017 | 278 | 0.140 |
Why?
|
| Joint Prosthesis | 1 | 2015 | 26 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 621 | 0.140 |
Why?
|
| Aged | 18 | 2020 | 18415 | 0.130 |
Why?
|
| Heart Valve Prosthesis | 1 | 2015 | 93 | 0.130 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2501 | 0.130 |
Why?
|
| Young Adult | 5 | 2018 | 5976 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Surgeons | 1 | 2019 | 238 | 0.130 |
Why?
|
| Survival Rate | 8 | 2009 | 1863 | 0.120 |
Why?
|
| Patient Selection | 3 | 2010 | 685 | 0.120 |
Why?
|
| Surgery Department, Hospital | 1 | 2014 | 42 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2013 | 292 | 0.120 |
Why?
|
| Transplantation, Homologous | 2 | 2010 | 996 | 0.110 |
Why?
|
| Radius | 2 | 2022 | 29 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 220 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2014 | 102 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2020 | 2261 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2014 | 111 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 582 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2014 | 533 | 0.110 |
Why?
|
| Sarcoma, Ewing | 2 | 2010 | 42 | 0.110 |
Why?
|
| Accreditation | 1 | 2012 | 60 | 0.110 |
Why?
|
| Arm Bones | 1 | 2011 | 2 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 153 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2014 | 300 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 860 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 318 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 307 | 0.100 |
Why?
|
| Knee Joint | 2 | 2002 | 168 | 0.100 |
Why?
|
| Osseointegration | 1 | 2010 | 11 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 1686 | 0.090 |
Why?
|
| Recurrence | 2 | 2011 | 1139 | 0.090 |
Why?
|
| Prognosis | 9 | 2006 | 3679 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2009 | 2438 | 0.090 |
Why?
|
| Surgical Procedures, Operative | 1 | 2011 | 182 | 0.090 |
Why?
|
| Lymphatic Metastasis | 4 | 2014 | 486 | 0.090 |
Why?
|
| Allografts | 2 | 2022 | 172 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 1673 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2014 | 2767 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2010 | 1204 | 0.080 |
Why?
|
| Eosinophilic Granuloma | 1 | 2008 | 10 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1036 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 1801 | 0.080 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 108 | 0.080 |
Why?
|
| Wound Healing | 1 | 2010 | 344 | 0.080 |
Why?
|
| Ileum | 1 | 2008 | 159 | 0.080 |
Why?
|
| Argon | 1 | 2007 | 10 | 0.070 |
Why?
|
| Laser Coagulation | 1 | 2007 | 54 | 0.070 |
Why?
|
| Clinical Protocols | 3 | 2010 | 156 | 0.070 |
Why?
|
| Risk Factors | 5 | 2020 | 5417 | 0.070 |
Why?
|
| Intergenerational Relations | 1 | 2005 | 5 | 0.070 |
Why?
|
| Age Factors | 3 | 2013 | 1851 | 0.070 |
Why?
|
| Thigh | 1 | 2005 | 38 | 0.070 |
Why?
|
| Prosthesis Implantation | 2 | 2005 | 125 | 0.070 |
Why?
|
| S100 Proteins | 1 | 2005 | 50 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 552 | 0.070 |
Why?
|
| Chicago | 2 | 2020 | 1379 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 379 | 0.060 |
Why?
|
| Radiography, Interventional | 1 | 2005 | 150 | 0.060 |
Why?
|
| Sclerotherapy | 1 | 2024 | 16 | 0.060 |
Why?
|
| Neoplasm Seeding | 1 | 2004 | 16 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 1169 | 0.060 |
Why?
|
| Proportional Hazards Models | 4 | 2003 | 859 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 999 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2008 | 397 | 0.060 |
Why?
|
| Histiocytosis, Sinus | 1 | 2003 | 14 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 388 | 0.060 |
Why?
|
| Histiocytoma, Benign Fibrous | 3 | 2003 | 25 | 0.060 |
Why?
|
| Muscle Proteins | 1 | 2003 | 132 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2014 | 357 | 0.050 |
Why?
|
| Chromans | 1 | 2002 | 30 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2014 | 678 | 0.050 |
Why?
|
| Incidence | 2 | 1999 | 1577 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2002 | 281 | 0.050 |
Why?
|
| Lymphoma | 1 | 2003 | 262 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2023 | 265 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 82 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2017 | 1753 | 0.050 |
Why?
|
| Sclerosis | 1 | 2021 | 28 | 0.050 |
Why?
|
| Tretinoin | 1 | 2002 | 126 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 223 | 0.050 |
Why?
|
| Thiazoles | 1 | 2002 | 131 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 6509 | 0.050 |
Why?
|
| Range of Motion, Articular | 2 | 1999 | 154 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2020 | 39 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2002 | 579 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2014 | 814 | 0.050 |
Why?
|
| Specialty Boards | 1 | 2020 | 24 | 0.050 |
Why?
|
| Vascular Patency | 1 | 2020 | 126 | 0.050 |
Why?
|
| Cytogenetic Analysis | 2 | 2010 | 71 | 0.050 |
Why?
|
| Bones of Upper Extremity | 1 | 1999 | 1 | 0.050 |
Why?
|
| Arthroplasty | 1 | 2020 | 27 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2013 | 468 | 0.050 |
Why?
|
| Safety Management | 1 | 2020 | 56 | 0.050 |
Why?
|
| Pathology, Clinical | 2 | 2010 | 33 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2002 | 429 | 0.050 |
Why?
|
| Spinal Nerve Roots | 1 | 1999 | 17 | 0.040 |
Why?
|
| World Health Organization | 2 | 2010 | 103 | 0.040 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 1999 | 19 | 0.040 |
Why?
|
| Bone Plates | 1 | 1999 | 23 | 0.040 |
Why?
|
| Reoperation | 2 | 1999 | 597 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 1999 | 17 | 0.040 |
Why?
|
| Neurilemmoma | 1 | 1999 | 34 | 0.040 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1999 | 43 | 0.040 |
Why?
|
| Sarcoma, Synovial | 2 | 2013 | 21 | 0.040 |
Why?
|
| Collagenases | 1 | 1999 | 39 | 0.040 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 107 | 0.040 |
Why?
|
| Epirubicin | 2 | 2009 | 14 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2019 | 41 | 0.040 |
Why?
|
| Ifosfamide | 2 | 2009 | 49 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 78 | 0.040 |
Why?
|
| Employment | 1 | 2019 | 52 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 1999 | 126 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2019 | 195 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2232 | 0.040 |
Why?
|
| Physicians | 1 | 2005 | 673 | 0.040 |
Why?
|
| Femur Head | 1 | 2017 | 8 | 0.040 |
Why?
|
| Recovery of Function | 1 | 1999 | 272 | 0.040 |
Why?
|
| Australia | 1 | 2017 | 99 | 0.040 |
Why?
|
| Professionalism | 1 | 2017 | 24 | 0.040 |
Why?
|
| Foot Diseases | 1 | 2017 | 12 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 247 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 235 | 0.040 |
Why?
|
| Disease Progression | 1 | 2001 | 1531 | 0.040 |
Why?
|
| Canada | 1 | 2017 | 204 | 0.040 |
Why?
|
| Spinal Diseases | 1 | 2017 | 44 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2005 | 1538 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2010 | 572 | 0.030 |
Why?
|
| Sports Medicine | 1 | 2017 | 56 | 0.030 |
Why?
|
| Hand | 1 | 2017 | 130 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2006 | 2262 | 0.030 |
Why?
|
| Athletic Injuries | 1 | 2017 | 91 | 0.030 |
Why?
|
| Algorithms | 1 | 2004 | 1830 | 0.030 |
Why?
|
| Apoptosis | 1 | 2002 | 1683 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2017 | 178 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 2894 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 229 | 0.030 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2013 | 5 | 0.030 |
Why?
|
| Liposarcoma | 1 | 2013 | 10 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2005 | 420 | 0.030 |
Why?
|
| Fibrosarcoma | 1 | 2013 | 84 | 0.030 |
Why?
|
| Leiomyosarcoma | 1 | 2013 | 40 | 0.030 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 1993 | 10 | 0.030 |
Why?
|
| Communication | 1 | 2017 | 441 | 0.030 |
Why?
|
| Prospective Studies | 2 | 1999 | 4214 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2013 | 160 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 596 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2005 | 1041 | 0.030 |
Why?
|
| Cell Movement | 2 | 2005 | 758 | 0.030 |
Why?
|
| Mutation | 1 | 2002 | 3968 | 0.030 |
Why?
|
| Foot Deformities | 1 | 1991 | 6 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 702 | 0.020 |
Why?
|
| Mice | 1 | 2005 | 11352 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 2360 | 0.020 |
Why?
|
| Gait | 1 | 1991 | 80 | 0.020 |
Why?
|
| France | 1 | 2010 | 47 | 0.020 |
Why?
|
| Cell Division | 2 | 2002 | 696 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1991 | 166 | 0.020 |
Why?
|
| Necrosis | 1 | 2009 | 204 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 295 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1993 | 1991 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 468 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2009 | 289 | 0.020 |
Why?
|
| Infant | 1 | 1994 | 3047 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 916 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2009 | 225 | 0.020 |
Why?
|
| Cisplatin | 1 | 2009 | 612 | 0.020 |
Why?
|
| S100 Calcium Binding Protein A6 | 1 | 2005 | 12 | 0.020 |
Why?
|
| Organizational Culture | 1 | 2005 | 33 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 469 | 0.020 |
Why?
|
| Data Collection | 1 | 2005 | 372 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 391 | 0.020 |
Why?
|
| Neurofibrosarcoma | 1 | 2003 | 3 | 0.010 |
Why?
|
| Ameloblastoma | 1 | 2003 | 7 | 0.010 |
Why?
|
| Hemangioendothelioma | 1 | 2003 | 9 | 0.010 |
Why?
|
| Desmin | 1 | 2003 | 10 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 2003 | 48 | 0.010 |
Why?
|
| Chordoma | 1 | 2003 | 19 | 0.010 |
Why?
|
| Myoglobin | 1 | 2003 | 29 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 204 | 0.010 |
Why?
|
| Sample Size | 1 | 2003 | 130 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2005 | 790 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 303 | 0.010 |
Why?
|
| HT29 Cells | 1 | 2002 | 49 | 0.010 |
Why?
|
| Synovitis, Pigmented Villonodular | 1 | 2002 | 3 | 0.010 |
Why?
|
| Chondroblastoma | 1 | 2002 | 5 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 2002 | 39 | 0.010 |
Why?
|
| Synovial Cyst | 1 | 2002 | 8 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2002 | 45 | 0.010 |
Why?
|
| Osteonecrosis | 1 | 2002 | 21 | 0.010 |
Why?
|
| Bursitis | 1 | 2002 | 11 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 87 | 0.010 |
Why?
|
| Lipoma | 1 | 2002 | 25 | 0.010 |
Why?
|
| Fibula | 1 | 2002 | 32 | 0.010 |
Why?
|
| Fibroma | 1 | 2002 | 33 | 0.010 |
Why?
|
| Osteomyelitis | 1 | 2002 | 54 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 265 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 303 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 122 | 0.010 |
Why?
|
| Hematoma | 1 | 2002 | 104 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 526 | 0.010 |
Why?
|
| beta Catenin | 1 | 2002 | 251 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 450 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 736 | 0.010 |
Why?
|
| Actins | 1 | 2003 | 451 | 0.010 |
Why?
|
| Polymethyl Methacrylate | 1 | 1999 | 12 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1384 | 0.010 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 1999 | 17 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 220 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 2378 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 2426 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1578 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 1999 | 193 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1961 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 1197 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1997 | 162 | 0.010 |
Why?
|
| Cause of Death | 1 | 1997 | 277 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 1458 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2003 | 1464 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2002 | 1565 | 0.010 |
Why?
|
| Prevalence | 1 | 1997 | 1239 | 0.010 |
Why?
|
| Electromyography | 1 | 1991 | 183 | 0.010 |
Why?
|
| Pain | 1 | 1991 | 391 | 0.010 |
Why?
|
| Animals | 1 | 2005 | 26582 | 0.000 |
Why?
|